{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:33:12Z","timestamp":1791891192105,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jneuroim.2021.577651","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:15:28Z","timestamp":1625098528000},"page":"577651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Genetic basis of Guillain-Barre syndrome"],"prefix":"10.1016","volume":"358","author":[{"given":"Shaghayegh","family":"Khanmohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Malekpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577651_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(77)91626-9","article-title":"HLA antigens in Guillain-Barre syndrome","volume":"2","author":"Adams","year":"1977","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0010","series-title":"Association of Matrix Metalloproteinase-9 (\u22121562 C\/T) Promoter Polymorphism with Disease Susceptibility and Severity in Patients with Guillain-Barr\u00e9 Syndrome in Bangladesh","author":"Ahmad","year":"2018"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0015","first-page":"179","article-title":"Guillain Barre syndrome in a family: a case report of four siblings","volume":"21","author":"Aquil","year":"2011","journal-title":"J. College Phys. Surg. Pakistan"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0020","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/adc.66.9.1078","article-title":"Guillain-Barre syndrome in three siblings less than 2 years old","volume":"66","author":"Bar-Joseph","year":"1991","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/0972-2327.104341","article-title":"A report of a probable case of familial Guillain Barre syndrome","volume":"15","author":"Barzegar","year":"2012","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jns.12292","article-title":"Increased incidence of axonal Guillain-Barr\u00e9 syndrome in La Spezia area of Italy: a 13-year follow-up study","volume":"24","author":"Benedetti","year":"2019","journal-title":"J. Peripher. Nervous Syst."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jns5.12074","article-title":"Genetics of Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions","volume":"19","author":"Blum","year":"2014","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2013.12.007","article-title":"Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barre syndrome","volume":"267","author":"Blum","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jneuroim.2018.07.016","article-title":"Genome-wide association study in Guillain-Barre syndrome","volume":"323","author":"Blum","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40744-018-0100-z","article-title":"Role of human leukocyte antigens (HLA) in autoimmune diseases","volume":"5","author":"Bodis","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2006.05.018","article-title":"Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes","volume":"177","author":"Caporale","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0165-5728(95)00079-H","article-title":"HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barre syndrome","volume":"61","author":"Chiba","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0070","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jnnp.55.6.508","article-title":"HLA antigens in familial Guillain-Barr\u00e9 syndrome","volume":"55","author":"Davidson","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2007.03.001","article-title":"Polymorphisms of CD1 genes in chronic dysimmune neuropathies","volume":"186","author":"De Angelis","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.08.001","article-title":"Th17 pathway signatures in a large Indian cohort of Guillain Barre syndrome","volume":"323","author":"Debnath","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1529-8027.2009.00216.x","article-title":"Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barre syndrome","volume":"14","author":"Dekker","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0090","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jneuroim.2016.07.020","article-title":"No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barre syndrome in a Brazilian population","volume":"298","author":"Dourado","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autrev.2016.09.022","article-title":"Guillain-Barre syndrome","volume":"16","author":"Esposito","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.410260619","article-title":"Gm haplotypes in inflammatory demyelinating polyneuropathies","volume":"26","author":"Feeney","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clineuro.2014.03.014","article-title":"Association of HLA-DR\/DQ polymorphisms with Guillain-Barre syndrome in Tunisian patients","volume":"121","author":"Fekih-Mrissa","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0115","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1212\/01.WNL.0000143055.09646.31","article-title":"The occurrence of Guillain-Barre syndrome within families","volume":"63","author":"Geleijns","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2004.01.003","article-title":"Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain\u2013Barr\u00e9 patients","volume":"150","author":"Geleijns","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.12.001","article-title":"Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain\u2013Barr\u00e9 syndrome","volume":"161","author":"Geleijns","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0130","first-page":"4211","article-title":"Mannose-binding lectin contributes to the severity of Guillain-Barre syndrome","volume":"177","author":"Geleijns","year":"2006","journal-title":"J. Immunol. (Baltimore, Md\u202f: 1950)"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jneuroim.2007.07.008","article-title":"Genetic polymorphisms of macrophage-mediators in Guillain-Barre syndrome","volume":"190","author":"Geleijns","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-5728(83)90058-9","article-title":"HLA-DR antigens in Mexican patients with Guillain-Barre syndrome","volume":"4","author":"Gorodezky","year":"1983","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/01677068509102324","article-title":"HLA-antigens in Guillain-Barre syndrome","volume":"2","author":"Hafez","year":"1985","journal-title":"J. Neurogenet."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0150","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/acn3.50884","article-title":"Human leukocyte antigen-DQB1 polymorphisms and haplotype patterns in Guillain-Barre syndrome","volume":"6","author":"Hayat","year":"2019","journal-title":"Annal. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192703","article-title":"FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barr\u00e9 syndrome","volume":"13","author":"Islam","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-010-8213-3","article-title":"Guillain-Barre syndrome--a classical autoimmune disease triggered by infection or vaccination","volume":"42","author":"Israeli","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0165","article-title":"Guillain-Barre syndrome outbreak in Peru: association with polymorphisms in IL-17, ICAM1, and CD1","volume":"7","author":"Jaramillo-Valverde","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0170","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/1744666X.2016.1193006","article-title":"Guillain-Barre syndrome: causes, immunopathogenic mechanisms and treatment","volume":"12","author":"Jasti","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0175","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s11033-011-0892-1","article-title":"Tumor necrosis factor alpha 308 G\/a polymorphism and Guillain-Barr\u00e9 syndrome risk","volume":"39","author":"Jiao","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131374","article-title":"Human leukocyte antigen DQB1 (HLA-DQB1) polymorphisms and the risk for Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"10","author":"Jin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2016.02.028","article-title":"Association of NOD1 and NOD2 polymorphisms with Guillain-Barre syndrome in Northern Indian population","volume":"363","author":"Kharwar","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0190","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/00207454.2016.1231186","article-title":"Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barre syndrome","volume":"127","author":"Kharwar","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0195","first-page":"429","article-title":"HLA alleles in patients with Guillain-Barre syndrome","volume":"113","author":"Li","year":"2000","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0200","doi-asserted-by":"crossref","first-page":"740947","DOI":"10.1155\/2014\/740947","article-title":"Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barr\u00e9 syndrome and downregulated by IVIg treatments","volume":"2014","author":"Li","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2016.07.029","article-title":"Polymorphisms in exon 2 of CD1 genes are associated with susceptibility to Guillain-Barre syndrome","volume":"369","author":"Liu","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jneuroim.2017.10.003","article-title":"Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: a systematic review and meta-analysis","volume":"313","author":"Liu","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0215","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.410440517","article-title":"Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome","volume":"44","author":"Ma","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.51.2.379","article-title":"HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome","volume":"51","author":"Ma","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0225","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(65)92313-5","article-title":"Familial Guillain-Barr\u00e9 syndrome","volume":"2","author":"MacGregor","year":"1965","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0230","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jnnp.2007.123943","article-title":"Immune responses to myelin proteins in Guillain\u2013Barr\u00e9 syndrome","volume":"79","author":"Makowska","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0235","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.410180417","article-title":"Alpha-1 antitrypsin phenotypes in demyelinating disease: an association between demyelinating disease and the allele PiM3","volume":"18","author":"McCombe","year":"1985","journal-title":"Ann. Neurol."},{"issue":"Suppl. 2","key":"10.1016\/j.jneuroim.2021.577651_bb0240","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/513786","article-title":"Differential distribution of HLA alleles in two forms of Guillain-Barre syndrome","volume":"176","author":"Monos","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/mus.20881","article-title":"Severe Guillain-Barre syndrome associated with chromosome 17p11.2\u201312 duplication","volume":"37","author":"Munch","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0250","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0165-5728(03)00133-4","article-title":"Interleukin-10 promoter polymorphisms in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"139","author":"Myhr","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/0972-2327.93278","article-title":"Familial Guillain-Barre syndrome: first Indian report","volume":"15","author":"Naik","year":"2012","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0260","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2009.10.018","article-title":"Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barr\u00e9 syndrome in Northern Indian population","volume":"218","author":"Nyati","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10048-003-0144-1","article-title":"Immunoglobulin KM genes in Guillain-Barre syndrome","volume":"4","author":"Pandey","year":"2003","journal-title":"Neurogenetics"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0270","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10048-005-0022-0","article-title":"Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barre syndrome","volume":"6","author":"Pandey","year":"2005","journal-title":"Neurogenetics"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/aian.AIAN_454_17","article-title":"Simultaneous occurrence of axonal Guillain-Barre syndrome in two siblings following dengue infection","volume":"21","author":"Pandey","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0280","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/0883073810388279","article-title":"Familial miller fisher syndrome","volume":"26","author":"Peeples","year":"2011","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0285","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1212\/WNL.45.7.1419-a","article-title":"HLA antigens in severe forms of Guillain-Barre syndrome","volume":"45","author":"Piradov","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0290","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/jnnp.74.7.971","article-title":"Apolipoprotein E genotypes and clinical outcome in Guillain-Barre syndrome","volume":"74","author":"Pritchard","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0295","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-5728(95)00102-8","article-title":"HLA-class II alleles in Guillain-Barre syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection","volume":"62","author":"Rees","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2012.03.006","article-title":"Fc receptor like 3 in Chinese patients of Han nationality with Guillain-Barr\u00e9 syndrome","volume":"246","author":"Sang","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0305","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4103\/neuroindia.NI_1045_15","article-title":"Familial Guillain-Barre syndrome: a case report with literature review","volume":"65","author":"Sarmah","year":"2017","journal-title":"Neurol. India"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0310","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00415-016-8237-6","article-title":"Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barre syndrome","volume":"263","author":"Schirmer","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0320","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4038\/cmj.v55i4.2638","article-title":"A case of possible familial Guillain-Barre syndrome","volume":"55","author":"Senanayake","year":"2010","journal-title":"Ceylon Med. J."},{"issue":"10280","key":"10.1016\/j.jneuroim.2021.577651_bb0325","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0330","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s00415-020-09742-2","article-title":"Axonal variants of Guillain-Barre syndrome: an update","volume":"268","author":"Shang","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0335","series-title":"Mechanism of Experimental Autoimmune Neuritis in Lewis Rats: The Dual Role of Macrophages","author":"Shin","year":"2013"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2009.01229.x","article-title":"Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barre syndrome","volume":"122","author":"Sinha","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/ecn.2019.0424","article-title":"Autoimmunity and cytokines in Guillain-Barr\u00e9 syndrome revisited: review of pathomechanisms with an eye on therapeutic options","volume":"30","author":"Soltani","year":"2019","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410040317","article-title":"HLA antigens in the Landry-Guillain-Barre syndrome and chronic relapsing polyneuritis","volume":"4","author":"Stewart","year":"1978","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0355","article-title":"Guillain-Barr\u00e9 syndrome: clinical profile and management","volume":"13","author":"Sudulagunta","year":"2015","journal-title":"Ger. Med. Sci."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0360","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00401-015-1466-4","article-title":"Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention","volume":"130","author":"Ubogu","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2021.577651_bb0365","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1529-8027.2011.00307.x","article-title":"Polymorphism of CD1 and SH2D2A genes in inflammatory neuropathies","volume":"16","author":"Uncini","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0165-5728(94)00185-Q","article-title":"Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases","volume":"58","author":"Van den Berg","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0375","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0380","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1212\/WNL.54.8.1661","article-title":"IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome","volume":"54","author":"van der Pol","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0385","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0390","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/WNL.55.5.705","article-title":"IgG Fc-receptor polymorphisms in Guillain-Barre syndrome","volume":"55","author":"Vedeler","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0395","series-title":"Guillain-Barr\u00e9 syndrome in Adults: Clinical Features and Diagnosis","author":"Vriesendorp","year":"2021"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0400","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"Guillain-Barr\u00e9 and miller fisher syndromes--new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0405","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1726-4901(09)70085-1","article-title":"Recurrent polyradiculoneuropathy and PMP22 defects","volume":"68","author":"Wang","year":"2005","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0410","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/564098","article-title":"Biomarkers of Guillain-Barre syndrome: some recent progress, more still to be explored","volume":"2015","author":"Wang","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0415","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14728222.2017.1258402","article-title":"Tumor necrosis factor-\u03b1 in Guillain-Barr\u00e9 syndrome, friend or foe?","volume":"21","author":"Wang","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jneuroim.2021.577651_bb0420","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1468-1331.1999.640499.x","article-title":"Familial Guillain\u2014Barr\u00e9 syndrome","volume":"6","author":"Wilmshurst","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0425","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2010.09.017","article-title":"Guillain Barre syndrome: clinical variants and their pathogenesis","volume":"231","author":"Winer","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-5728(88)90130-0","article-title":"HLA antigens in the Guillain-Barre syndrome","volume":"18","author":"Winer","year":"1988","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0435","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jneuroim.2011.12.003","article-title":"The effect of TNF-alpha, FcgammaR and CD1 polymorphisms on Guillain-Barre syndrome risk: evidences from a meta-analysis","volume":"243","author":"Wu","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0440","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0022-3476(95)70539-2","article-title":"Familial Guillain-Barr\u00e9 syndrome subsequent to Campylobacter jejuni enteritis","volume":"126","author":"Yuki","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0445","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1582-4934.2008.00333.x","article-title":"Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline","volume":"13","author":"Zhang","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jneuroim.2021.577651_bb0450","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10072-018-3563-3","article-title":"Association of CD1 and FcgammaR gene polymorphisms with Guillain-Barre syndrome susceptibility: a meta-analysis","volume":"39","author":"Zhang","year":"2018","journal-title":"Neurol. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:01Z","timestamp":1759048861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":90,"alternative-id":["S0165572821001788"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577651","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic basis of Guillain-Barre syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577651"}}